Open menu Close menu Open Search Close search

AMERICAN DRUGS | ANATOMY | HEALTH TOPICS | HIV/AIDS GLOSSARY | DISEASES | HEALTH ARTICLES | GENOME | OCCUPATIONS

Fevaxyn Pentofel

Spanish Simplified Chinese French German Russian Hindi Arabic Portuguese















Summary for the public


What is Fevaxyn Pentofel?

Fevaxyn Pentofel is a vaccine for cats which is a solution for injection in a prefilled syringe. Fevaxyn Pentofel contains the following inactivated viruses: Feline Panleukopenia Virus, Feline Rhinotracheitis Virus, Feline Calicivirus, Feline Leukaemia Virus, and the inactivated bacterium Feline Chlamydia psittaci.


What is Fevaxyn Pentofel used for?

Fevaxyn Pentofel is used to immunise healthy cats of 9 weeks or older against Feline Panleukopenia and Feline Leukaemia and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci.

The contents of the prefilled syringe are shaken and given by subcutaneous (under the skin) injection.

For cats 9 weeks and older, two doses are given at an interval of 3 to 4 weeks. An additional dose is recommended for kittens living in high-risk areas for Feline Leukaemia Virus whose first dose was administered before 12 weeks of age. Fevaxyn Pentofel is then given once every year.


How does Fevaxyn Pentofel work?

Fevaxyn Pentofel contains small amounts of four inactivated viruses and one inactivated bacterium.

When injected, this small exposure helps the cat’s immune system to recognise and attack the viruses and bacterium. When exposed to any of these viruses and bacterium later in life, the cat will either not become infected or will have a much less serious infection.


How has the effectiveness of Fevaxyn Pentofel been studied?

Fevaxyn Pentofel has been studied against Feline Leukaemia, against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci, as well as against disease caused by Feline Panleukopenia virus.

In addition, studies in cats of various breeds were carried out to observe any side effects of Fevaxyn Pentofel after the first and second vaccinations.


What benefit has Fevaxyn Pentofel shown during the studies?

Fevaxyn Pentofel has been shown to be effective against Feline Leukaemia, against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci, as well as against disease caused by Feline Panleukopenia virus.

In the trial to observe side effects, there were no side effects in 94.2% of cats for the first vaccination and no side effects observed for 99% of cats for the second vaccination.


What are the side effects of Fevaxyn Pentofel?

Some vaccinated cats may develop reactions to the vaccine, which include temporary fever, vomiting, anorexia (not eating), and/or depression, which usually disappear within 24 hours.

Occasionally there is swelling, pain, pruritus (itching) or hair loss at the injection site. In very rare cases there is an anaphylactic reaction (severe allergy) with oedema (fluid under the skin), pruritus, respiratory and cardiac distress, severe gastrointestinal signs or shock during the first hours after vaccination.


What are the precautions for the person who gives the medicine or comes into contact with the animal?

Fevaxyn Pentofel contains mineral oil. Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – rarely causing the loss of a finger. If someone is accidentally injected with this product, they must seek immediate medical advice even if only a very small amount is injected. The Package Leaflet should be taken to the doctor. If pain persists for more than 12 hours after medical examination, the doctor should be contacted again.


Why has Fevaxyn Pentofel been approved?

The Committee for Medicinal ,Products for Veterinary Use (CVMP) agreed that the benefits of Fevaxyn Pentofel are greater than any risks to immunise healthy cats of 9 weeks or older against feline viruses. They recommended that Fevaxyn Pentofel should be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.


Other information about Fevaxyn Pentofel:

The European Commission granted a marketing authorisation valid throughout the European Union, for Fevaxyn Pentofel to Fort Dodge Laboratories Ireland on 5 February 1997. Information on the prescription status of this product may be found on the outer package.

Authorisation details
Name: Fevaxyn Pentofel
EMEA Product number: EMEA/V/C/000030
Active substance: Adjuvanted inactivated vaccine against feline panleukopenia and feline leukaemia and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydophila felis
INN or common name: Adjuvanted inactivated vaccine against feline panleukopenia and feline leukaemia and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydophila felis
Species: Cats
ATCvet Code: QI06AL01
Marketing Authorisation Holder: Fort Dodge Laboratories (Ireland)
Revision: 10
Date of issue of Market Authorisation valid throughout the European Union: 05/02/1997
Contact address:
Fort Dodge Laboratories Ireland
Finisklin Industrial Estate
Sligo
Ireland



  • Drugs Alphabetically





    • Product Characteristics

    ANNEX I

    SUMMARY OF PRODUCT CHARACTERISTICS


    1. NAME OF VETERINARY THE MEDICINAL PRODUCT
    Fevaxyn Pentofel, solution for injection, for cats
    2. QUALITATIVE AND QUANTITATIVE COMPOSITION
    Per dose of 1ml (single dose syringe):
    Active components
    Relative Potency (R.P.)
    Inactivated Feline Panleukopenia Virus
    (CU4 strain)
    Inactivated Feline Calicivirus
    (255 strain)
    Inactivated Feline Rhinotracheitis Virus
    (605 strain)
    Inactivated Chlamydophila felis
    (Cello strain)
    Inactivated Feline Leukemia Virus
    (61E strain)
    9.50 - 12.25
    1.65 – 2.15
    1.60 – 2.10
    2.00 – 2.30
    1.45 – 2.0
    Adjuvants
    Ethylene/Maleic Anhydride (EMA)
    Neocryl A640
    Emulsigen SA
    10mg
    30mg
    50mg
    For a full list of excipients, see Section 6.1
    3. PHARMACEUTICAL FORM
    Solution for injection.
    4. CLINICAL PARTICULARS
    4.1 Target species
    Cats
    4.2 Indications for use, specifying the target species
    For the active immunisation of healthy cats 9 weeks or older against Feline Panleukopenia and Feline
    Leukaemia viruses and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline
    Calicivirus and Chlamydophila felis. S
    4.3 Contraindications
    None
    2/18
     
    4.4 Special warnings
    Vaccination does not affect the course of FeLV infection in cats already infected with FeLV at the
    time of vaccination, implying that such cats will excrete FeLV irrespective of vaccination;
    consequently, these animals will constitute a hazard to susceptible cats in their environment. It is
    therefore recommended that cats with a significant risk of having been exposed to FeLV be tested for
    FeLV antigen prior to vaccination. Test negative animals can be vaccinated, while test-positive cats
    should be isolated from other cats and retested within 1-2 months. Cats positive at the second testing
    should be considered as being permanently infected with FeLV and should be handled accordingly.
    Cats negative at second testing can be vaccinated since, in all likelihood, they have overcome the
    FeLV infection.
    4.5 Special precautions for use
    Special precautions for use in animals
    In case of anaphylactoid reaction, adrenaline should be administered intramuscularly.
    Vaccination of FeLV positive cats is of no benefit. See Section 4.4 for further details.
    Special precautions to be taken by the person administering the veterinary medicinal product to
    animals
    To the user:
    This product contains mineral oil. Accidental injection/self injection may result in severe pain and
    swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the
    affected finger if prompt medical attention is not given.
    If you are accidentally injected with this product, seek prompt medical advice even if only a very
    small amount is injected and take the package insert with you.
    If pain persists for more than 12 hours after medical examination, seek medical advice again.
    To the physician:
    This product contains mineral oil. Even if small amounts have been injected, accidental injection with
    this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even
    the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision
    and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
    4.6 Adverse reactions (frequency and seriousness)
    Vaccinated cats may develop post-vaccinal reactions including transient fever, vomiting, anorexia
    and/or depression which usually disappear within 24 hours.
    A local reaction with swelling, pain, pruritis or hair loss at the injection site may be observed.
    In very rare cases an anaphylactoid reaction with oedema, pruritis, respiratory and cardiac distress,
    severe gastrointestinal signs or shock has been seen during the first hours after vaccination. See
    Section 4.5 for guidance about treatment.
    4.7 Use during pregnancy, lactation or lay
    The safety of the vaccine in pregnant queens has not been investigated. Vaccination of pregnant
    queens is not recommended.
    3/18
     
    4.8 Interaction with other medicinal products and other forms of interaction
    No information is available on the safety and efficacy of this vaccine when used with any other
    veterinary medicinal product. A decision to use this vaccine before or after any other veterinary
    medicinal product therefore needs to be decided on a case by case basis.
    4.9 Amounts to be administered and administration route
    The contents of the single dose syringe should be shaken well and administered aseptically by
    subcutaneous injection. When administering the product, care must be taken to attach the enclosed
    sterile needle aseptically to the syringe before use.
    Basic vaccination of cats 9 weeks and older: two doses at an interval of 3 to 4 weeks. An additional
    dose is recommended for kittens living in high-risk FeLV environments whose first dose was
    administered before 12 weeks of age.
    Revaccination: one vaccination annually.
    4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
    No undesirable effects other than those observed and mentioned in section 4.6 “Adverse Reactions”
    have been observed.
    4.11 Withdrawal period(s)
    Not applicable.
    5. IMMUNOLOGICAL PROPERTIES
    ATC vet code: QI06AL01
    Fevaxyn Pentofel stimulates the development of active immunity against Feline Panleukopenia Virus,
    Feline Rhinotracheitis Virus, Feline Calicivirus, Chlamydophila felis and Feline Leukaemia Virus.
    6. PHARMACEUTICAL PARTICULARS
    6.1 List of excipients
    Eagles Earles Minimal Essential Medium with Hepes buffer and Lactalbumin hydrolysate
    6.2 Incompatibilities
    Do not mix with any other veterinary medicinal product.
    6.3 Shelf life
    1 year
    6.4 Special precautions for storage
    Store and transport refrigerated (2 o C – 8 o C)
    Do not freeze.
    Protect from light.
    4/18
    6.5 Nature and composition of immediate packaging
    Single dose disposable polypropylene syringes containing one dose (l ml) of vaccine. The syringes are
    sealed with rubber tips.
    Packaging:
    One cardboard box containing 10, 20 or 25 single dose (1 ml) pre-filled syringes and 10, 20 or 25
    sterile needles respectively.
    Not all pack sizes may be marketed.
    6.6 Special precautions for the disposal of unused veterinary medicinal product or waste
    materials derived from the use of such products
    Any unused product or waste materials derived from such veterinary medicinal products should be
    disposed of in accordance with national requirements.
    7. MARKETING AUTHORISATION HOLDER
    Pfizer Limited
    Ramsgate Road
    Sandwich, Kent
    CT13 9NJ
    United Kingdom
    8. MARKETING AUTHORISATION NUMBER(S)
    EU/2/96/002/001-003
    9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
    Date of first authorisation: 5 February 1997
    Date of last renewal: 27 February 2007
    10. DATE OF REVISION OF THE TEXT
    6 August 2010
    Detailed information on this veterinary medicinal product is available on the website of the European
    Medicines Agency (EMA) http://www.ema.europa.eu
    PROHIBITION OF SALE, SUPPLY AND/OR USE
    Not applicable.
    5/18
    ANNEX II
    A.
    MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S)
    AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE
    FOR BATCH RELEASE
    B.
    CONDITIONS OR RESTRICTIONS OF THE MARKETING
    AUTHORISATION REGARDING SUPPLY OR USE
    C.
    CONDITIONS OR RESTRICTIONS OF THE MARKETING
    AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
    D.
    STATEMENT OF THE MRLs
    E.
    SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING
    AUTHORISATION HOLDER
    6/18
    A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
    MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
    RELEASE
    Names and addresses of the manufacturers of the biological active substances
    Fort Dodge Laboratories Ireland
    Finisklin Industrial Estate
    Sligo
    Ireland
    Fort Dodge Charles City
    2000 Rockford Road
    Charles City
    Iowa 50616
    USA
    Name and address of the manufacturer responsible for batch release
    Fort Dodge Laboratories Ireland
    Finisklin Industrial Estate
    Sligo
    Ireland
    B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION
    REGARDING SUPPLY OR USE
    To be supplied only on veterinary prescription.
    C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH
    REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
    Not applicable.
    D. STATEMENT OF THE MRLs
    Not applicable.
    E. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING
    AUTHORISATION HOLDER
    Not applicable.
    7/18
     
    ANNEX III
    LABELLING AND PACKAGE LEAFLET
    8/18
    A. LABELLING
    9/18
    PARTICULARS TO APPEAR ON THE OUTER PACKAGE
    10 x 1 ml single dose syringes
    20 x 1 ml single dose syringes
    25 x 1 ml single dose syringes
    1. NAME OF VETERINARY THE MEDICINAL PRODUCT
    Fevaxyn Pentofel
    2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES
    Inactivated adjuvanted vaccine for cats.
    Per dose of 1ml:
    Inactivated FPV (RP 9.50 - 12.25); FCV (RP 1.65 – 2.15); FVR (RP 1.60 – 2.10); Chlam (RP 2.00 –
    2.30); FeLV (RP1.45 – 2.0)
    3. PHARMACEUTICAL FORM
    Solution for injection.
    4. PACKAGE SIZE
    10 x 1 ml single dose syringes
    20 x 1 ml single dose syringes
    25 x 1 ml single dose syringes
    5. TARGET SPECIES
    Cats
    6. INDICATION(S)
    For the active immunisation of healthy cats 9 weeks or older against Feline Panleukopenia and Feline
    Leukaemia viruses and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline
    Calicivirus and Chlamydophila felis. S
    7. METHOD AND ROUTE(S) OF ADMINISTRATION
    Administer aseptically by subcutaneous injection.
    Read the package leaflet before use.
    8. WITHDRAWAL PERIOD
    Not applicable.
    10/18
     
    9. SPECIAL WARNING(S), IF NECESSARY
    Accidental injection is dangerous – read package leaflet before use.
    10. EXPIRY DATE
    EXP {month/year}
    11. SPECIAL STORAGE CONDITIONS
    Store and transport refrigerated (2°C - 8°C).
    Do not freeze.
    Keep the syringes in the outer carton in order to protect from light.
    12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
    WASTE MATERIALS, IF ANY
    Disposal: read package leaflet.
    13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
    RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
    For animal treatment only - to be supplied only on veterinary prescription.
    14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
    Keep out of the reach and sight of children.
    15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
    Pfizer Limited
    Ramsgate Road
    Sandwich, Kent
    CT13 9NJ
    United Kingdom
    16. MARKETING AUTHORISATION NUMBER(S)
    EU/2/96/002/001 10 x 1 ml
    EU/2/96/002/002 20 x 1 ml
    EU/2/96/002/003 25 x 1 ml
    17. MANUFACTURER’S BATCH NUMBER
    Batch
    11/18
     
    MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
    1 x 1 ml dose
    1. NAME OF VETERINARY THE MEDICINAL PRODUCT
    Fevaxyn Pentofel for cats
    2. QUANTITY OF THE ACTIVE SUBSTANCE(S)
    Inactivated FPV, FCV, FVR, Chlam, FeLV
    3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
    1 ml (1 dose)
    4. ROUTE(S) OF ADMINISTRATION
    SC
    5. WITHDRAWAL PERIOD
    Not applicable
    6. BATCH NUMBER
    Batch
    7. EXPIRY DATE
    EXP {month/year}
    8. THE WORDS “FOR ANIMAL TREATMENT ONLY”
    For animal treatment only.
    12/18
     
    B. PACKAGE LEAFLET
    13/18
    PACKAGE LEAFLET FOR:
    Fevaxyn Pentofel, solution for injection, for cats
    1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
    THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
    RELEASE, IF DIFFERENT
    Marketing authorisation holder and manufacturer:
    Pfizer Limited
    Ramsgate Road
    Sandwich, Kent
    CT13 9NJ
    United Kingdom
    Manufacturer for the batch release:
    Fort Dodge Laboratories Ireland
    Finisklin Industrial Estate
    Sligo
    Ireland
    2. NAME OF VETERINARY THE MEDICINAL PRODUCT
    Fevaxyn Pentofel, solution for injection, for cats
    3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
    Per dose of 1ml (single dose syringe):
    Active components
    Relative Potency (R.P.)
    Inactivated Feline Panleukopenia Virus
    (CU4 strain)
    Inactivated Feline Calicivirus
    (255 strain)
    Inactivated Feline Rhinotracheitis Virus
    (605 strain)
    Inactivated Chlamydophila felis
    (Cello strain)
    Inactivated Feline Leukaemia Virus
    (61E strain)
    9.50 - 12.25
    1.65 – 2.15
    1.60 – 2.10
    2.00 – 2.30
    1.45 – 2.0
    Adjuvants
    Ethylene/Maleic Anhydride (EMA)
    Neocryl A640
    Emulsigen SA
    10mg
    30mg
    50mg
    4. INDICATION(S)
    For the active immunisation of healthy cats 9 weeks or older against Feline Panleukopenia and Feline
    Leukaemia viruses and against respiratory diseases caused by Feline Rhinotracheitis virus, Feline
    Calicivirus and Feline Chlamydophila felis.
    14/18
     
    5. CONTRAINDICATIONS
    Do not use in pregnant cats.
    6. ADVERSE REACTIONS
    Vaccinated cats may develop post-vaccinal reactions including transient fever, vomiting, anorexia
    and/or depression which usually disappear within 24 hours.
    A local reaction with swelling, pain, pruritis or hair loss at the injection site may be observed.
    In very rare cases an anaphylactoid reaction with oedema, pruritis, respiratory and cardiac distress,
    severe gastrointestinal signs or shock has been seen during the first hours after vaccination.
    Overdose: No undesirable effects other than those mentioned above have been observed.
    If you notice any serious effects or other effects not mentioned in this leaflet, please inform your
    veterinary surgeon.
    7. TARGET SPECIES
    Cats
    8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
    1 ml. Subcutaneous use.
    The contents of the single dose prefilled syringe should be shaken well and administered aseptically
    by subcutaneous injection. When administering the product, care must be taken to attach the enclosed
    sterile needle aseptically to the syringe before use.
    Primary vaccination of cats 9 weeks and older: two doses at an interval of 3 to 4 weeks. An additional
    dose is recommended for kittens living in high-risk FeLV environments whose first dose was
    administered before 12 weeks of age.
    Revaccination: one vaccination annually.
    9. ADVICE ON CORRECT ADMINISTRATION
    10. WITHDRAWAL PERIOD
    Not applicable.
    11. SPECIAL STORAGE PRECAUTIONS
    Keep out of the reach and sight of children.
    Store and transport refrigerated (2°C - 8°C).
    Keep the syringes in the outer carton in order to protect from light.
    Do not freeze.
    15/18
    12. SPECIAL WARNING(S)
    Vaccination does not affect the course of FeLV infection in cats already infected with FeLV at the
    time of vaccination, implying that such cats will excrete FeLV irrespective of vaccination;
    consequently, these animals will constitute a hazard to susceptible cats in their environment. It is
    therefore recommended that cats with a significant risk of having been exposed to FeLV be tested for
    FeLV antigen prior to vaccination. Test negative animals can be vaccinated, while test-positive cats
    should be isolated from other cats and retested within 1-2 months. Cats positive at the second testing
    should be considered as being permanently infected with FeLV and should be handled accordingly.
    Cats negative at second testing can be vaccinated since, in all likelihood, they have overcome the
    FeLV infection.
    No information is available on the safety and efficacy of this vaccine when used with any other
    veterinary medicinal product. A decision to use this vaccine before or after any other veterinary
    medicinal product therefore needs to be decided on a case by case basis.
    Do not mix with any other veterinary medicinal product.
    Special precautions for use in animals
    In case of an anaphylactoid reaction, adrenaline should be administered intramuscularly.
    Special precautions to be taken by the person administering the veterinary medicinal product to
    animals
    To the user:
    This product contains mineral oil. Accidental injection/self injection may result in severe pain and
    swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the
    affected finger if prompt medical attention is not given.
    If you are accidentally injected with this product, seek prompt medical advice even if only a very
    small amount is injected and take the package leaflet with you.
    If pain persists for more than 12 hours after medical examination, seek medical advice again.
    To the physician:
    This product contains mineral oil. Even if small amounts have been injected, accidental injection with
    this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even
    the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision
    and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
    13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE
    MATERIALS, IF ANY
    Any unused product or waste material derived from such veterinary medicinal products should be
    disposed of in accordance with national requirements.
    14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
    6 August 2010
    Detailed information on this product is available on the website of the European Medicines Agency
    16/18
     
    15. OTHER INFORMATION
    10 x 1 ml presentation: Box containing 10 single dose prefilled syringes and 10 sterile needles.
    20 x 1 ml presentation: Box containing 20 single dose prefilled syringes and 20 sterile needles.
    25 x 1 ml presentation: Box containing 25 single dose prefilled syringes and 25 sterile needles.
    Not all pack sizes may be marketed.
    For any information about this veterinary medicinal product, please contact the local representative of
    the marketing authorisation holder.
    België/Belgique/Belgien
    Pfizer Animal Health s.a.,
    Tél.: +32 (0)2 554 62 11
    Luxembourg
    Pfizer Animal Health s.a.,
    Tél.: + 32 (0)2 554 62 11
    Република България
    Pfizer Luxembourg SARL
    Tel: + 359 2 970 41 71
    Magyarország
    Pfizer Kft.
    Tel: +361 488 3695
    Česká Republika
    Pfizer Animal Health
    Tel: +420 283 004 111
    Malta
    Agrimed Limited
    Tel: +356 21 465 797
    Danmark
    Pfizer Oy Animal Health,
    Tlf: +358 (0)9 4300 40
    Nederland
    Pfizer Animal Health B.V.,
    Tel: +31 (0)10 4064 600
    Deutschland
    Pfizer GmbH
    Tel: + 49 30-5500 5501
    Norge
    Pfizer Oy Animal Health,
    Tlf: +358 (0)9 4300 40
    Eesti
    Pfizer Animal Health
    Tel: +370 5 269 17 96
    Österreich
    Pfizer Corporation Austria Ges.m.b.H.
    Tel: +43 (0)1 52 11 57 20
    Ελλάδα
    Pfizer Hellas A.E.
    Τηλ.: +30 210 6785800
    Polska
    Pfizer Trading Polska Sp. z.o.o.
    Tel: +48 22 335 62 00
    España
    Pfizer S.A.
    Tel: +34 91 4909900
    Portugal
    Laboratórios Pfizer, Lda.
    Tel: +351 21 423 55 00
    France
    Pfizer
    Tél: +33 (0)1 58 07 46 00
    Romania
    Pfizer Romania SRL
    Tel: + 0040 21 207 28 93
    Ireland
    Pfizer Healthcare Ireland, Trading As:
    Pfizer Animal Health
    Tel: +353 (0) 1 467 6500
    Slovenija
    Pfizer Luxembourg SARL
    Tel: +386 (0) 1 52 11 670
    Ìsland
    Pfizer Oy Animal Health,
    Tel: +358 (0)9 4300 40
    Slovenská Republika
    Pfizer Luxembourg SARL o.z.
    Tel: + 421 2 3355 5500
    17/18
    Italia
    Pfizer Italia S.r.l.,
    Tel: +39 06 3318 2933
    Suomi/Finland
    Pfizer Oy Animal Health,
    Puh/Tel: +358 (0)9 4300 40
    Kύπρος
    Pfizer Hellas A.E.
    Τηλ.: +30 210 6785800
    Sverige
    Pfizer Oy Animal Health,
    Tel: +358 (0)9 4300 40
    Latvija
    Pfizer Animal Health
    Tel: +370 5 269 17 96
    United Kingdom
    Pfizer Ltd
    Tel: +44 (0) 1304 616161
    Lietuva
    Pfizer Animal Health
    Tel: +370 5 269 17 96
    18/18


    Source: European Medicines Agency


    - Please bookmark this page (add it to your favorites).
    - If you wish to link to this page, you can do so by referring to the URL address below this line.

    https://theodora.com/drugs/eu/fevaxyn_pentofel_veterinary.html

    Copyright © 1995-2021 ITA all rights reserved.